Business

Lilly Reports Strong Revenue Growth, GLP-1 Drugs Drive Sales

Updated 2026-08-05 11:10 UTC 1 source Positive

Lilly reported a 48% revenue increase driven by high demand for its GLP-1 drugs Mounjaro and Zepbound. The company's sales were significantly higher than expected.

Coverage timeline — 2 articles

MarketWatch

Is it a bad time to buy a home? Buyers say yes, data show.

More people are hitting pause on buying a home, as surging mortgage rates continue to hinder the housing market.

2026-08-05 11:00 UTC

MarketWatch

Lilly’s revenue soars 48%, driven by demand of its GLP-1s

Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

2026-08-05 11:04 UTC